Choroidal neovascularization associated with pathological myopia
Conditions
Interventions
Intravitreal ranibizumab injection
Intravitreal bevacizumab injection
Sponsors
Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) spherical equivalent refractive error of -6.0 dioptres (D) or more (an eye that had a spherical equivalent less than –6.0 D was eligible if there were retinal abnormalities consistent with PM, such as lacquer cracks, chorioretinal atrophy or posterior staphyloma, and if the axial length of the eye was at least 26.5 mm); 2) treatment for naïve subfoveal myopic CNV; subfoveal location was defined as the presence of CNV under the geometric center of the foveal vascular zone and confirmed on fluorescein angiography (FA); 3) baseline best-corrected visual acuity (BCVA) between 20/32 and 20/400, both inclusive. Only females at least 12 months post menopause or using standard forms of contraception in the fertile age could be included.
Exclusion criteria
Exclusion criteria: 1) intraocular surgery of any kind within six months of the day of injection, 2) any other ocular disease that could compromise vision in the study eye, 3) ocular hypertension or glaucoma 4) uncontrolled systemic hypertension; peripheral vascular disease and history of thromboembolism, ischemic heart disease or stroke.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| The changes in mean central macular thickness, the mean number of injections administered in each group, and the change in mean CNV area. | — |
Primary
| Measure | Time frame |
|---|---|
| The change in mean best-corrected visual acuity (BCVA) and the proportion of eyes improving in BCVA by > 1 and > 3 lines at the 18-month examination. | — |
Countries
Europe
Contacts
Public ContactProf. Francesco Bandello
University Vita-Salute, Scientific Institute San Raffaele Department of Ophthalmology
Outcome results
None listed